

ANEXO 4. Estudios excluidos de nuestro trabajo, motivos de la exclusión de la revisión sistemática y citas bibliográficas.

ESTUDIOS EXCLUIDOS EN NUESTRO TRABAJO

Estudio (primer autor, año)	Motivo de exclusión de la revisión sistemática
Barrueco 2017	
Chibana 2011	
Duong-Quy 2009	
Fritz 2011	
Hidalgo Sierra 2018	
Kaufmann 2009	
Lorenzo 2017	Uso del miniespirómetro Piko-6
Midodzi 2013	
Peixoto 2018	
Sichletidis 2011	
Toda 2009	
Van den Bemt 2014	
Wada 2010	
Pérez Padilla 2013	Otros espirómetros portátiles
Kozaki 2011	Uso espirómetro Hi-Check (análogo a COPD-6), sin valore numéricos
Akpınar 2006	
Castillo 2009	
Castillo 2015	
Pérez Padilla 2013	Uso de espirometría convencional
Price 2009	
Stratelis 2004	
Stratelis 2006	

ANEXO 4. Estudios excluidos de nuestro trabajo, motivos de la exclusión de la revisión sistemática y citas bibliográficas.

Stupnytska 2013	
Vandevoorde 2005	
Antón 2016	Uso del miniespirómetro COPD-6 sin utilidad diagnóstica
Muller 2012	
Schermer 2018	Realización a todos o parte de pacientes incluidos de COPD-6 y/o cuestionario, no se realiza espirometría
Sui 2015	
Yawn 2014	
Moranta 2015	A los enfermos les realiza cuestionario, si es positivo, les realiza COPD-6, y si VEF1/VEF6 <0,75 les deriva a espirometría convencional
Banka 2017	Compara espirometría convencional con Peak-flow portátil, no usa espirómetro portátil
Kjeldgaard 2017	Se realiza COPD-6 en todos los pacientes, pero en un bajo porcentaje de enfermos (949/2990) se realizó la prueba oro, la espirometría convencional
Banka 2017	Este estudio compara espirometría convencional con Peak-flow portátil, no realiza COPD-6
Dickens 2017	Uso de monitor pulmonar Vitalograph, no de un miniespirómetro.

CITAS BIBLIOGRÁFICAS DE LOS ESTUDIOS EXCLUIDOS DEL METAANÁLISIS.

- A. Akpinar-Elci M, Fedan KB, Enright PL. FEV6 as a surrogate for FVC in detecting airways obstruction and restriction in the workplace. *Eur Respir J* 2006; 27: 374-7.
- B. Castillo D, Guayta R, Giner J. COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study FARMAEPOC group. *Respir Med* 2009;103: 839-45
- C. Castillo D, Burgos F, Guayta R. Airflow obstruction case finding in community-pharmacies: a novel strategy to reduce COPD underdiagnosis. *Respir Med* 2015; 109: 475-82.
- D. Pérez-Padilla R, Wehrmeister FC, Celli BR. Reliability of FEV1/FEV6 to diagnose airflow obstruction compared with FEV1/FVC: the PLATINO longitudinal study. *PLOS ONE* 2013; 8 (8): 1-7.
- E. Price D, Crockett A. Spirometry in primary care case-identification, diagnosis and management of COPD. *Prim Care Respir J* 2009 Sep;18(3):216-23
- F. Stratelis G, Jakobsson P, Molstad S. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. *Br J Gen Pract*. 2004 Mar; 54(500): 201–206.
- G. Stratelis G, Mölstad S, Jakobsson P. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. *Scand J Prim Health Care* 2006; 24 (3): 133-9

ANEXO 4. Estudios excluidos de nuestro trabajo, motivos de la exclusión de la revisión sistemática y citas bibliográficas.

- H. Stupnytska G. Use FEV6 and FEV1/FEV6 as alternative indicators in the diagnosis of bronchial obstruction in primary care. European Respiratory Journal 2013; 42: P1259.
- I. Vandevenne J, Verbanck S, Schuermans D. FEV1/FEV6 and FVC as an alternative for FEV1/FVC and FVC in the spirometric detection of airway obstruction and restriction. Chest 2005; 127: 1560-4.
- J. Barrueco Ferrero M, Hidalgo Sierra V, Hernández Mezquita M. Real-life data: Utility of micro-spirometer Piko-6 for diagnosis of COPD in Primary Care. Am J Respir Crit Care Med 2017; 195: A2511.
- K. Chibana K, Ishii Y, Anraku Y. Prevalence of airflow limitation in patients diagnosed and treated for symptoms of chronic bronchitis by general practitioners in Tochigi prefecture ,Japan. Intern Med 2011; 50: 2277 – 83.
- L. Duong-Quy S, Hua-Huy T, Mai-Huu-Thanh B. Détection précoce de la bronchopneumopathie chronique obstructive post-tabagique au Viet Nam. Rev Mal Respir 2009; 26: 267 – 74.
- M. Fritz P, Crockett A, Beilby J. Simplified COPD screening: validation of the PiKo-6 in primary care. Prim Care Respir J 2011; 20 (2): 190-8
- N. Hidalgo Sierra V Hernández Mesquita MA. Usefulness of the piko-6 portable device for early COPD detection in primary care. Arch Bronconeumol 2018; 54(9): 460-6.
- O. Kaufmann M, Hartl S, Geyer K. Measuring FEV(6) for detecting early airway obstruction in the primary care setting. Quality and utility of the new PiKo-6 device. Respiration. 2009;78(2):161-7
- P. Lorenzo Hernández MV. Usefulness of the FEV1/FEV6 ratio to detect the prevalence of lung obstruction in hospitalised patients with multiple morbidities. Rev Esp Geriatr Gerontol. 2017 Jul - Aug;52(4):193-196
- Q. Midodzi WK, Mayers I, Rowe B. Validity of the Piko-6 portable device for screening for obstructive airway disease in a community pharmacy practice. American Journal of Respiratory and Critical Care Medicine 2013;187:A2846
- R. Peixoto I, Martins A, Silva AI. Chronic Obstructive Pulmonary Disease: validation of IPAG questionnnaire and Piko-6 device, in Portuguese Primary Health Care Units. Rev Pat Respir 2018; 21(1): 4-10.
- S. Sichletidis L, Spyros D, Papaioannou M. A combination of the IPAG questionnaire and PiKo-6 flow meter is a valuable screening tool for COPD in the primary care setting. Prim Care Respir J 2011; 20(2): 184-9.
- T. Toda R. Validation of "Lung Age" measured by spirometry and handy electronic FEV1/FEV6 meter in pulmonary diseases. Intern Med 2009; 48: 513-21.
- U. van den Bemt L, Wouters BCW, Grootens J. Diagnostic accuracy of pre-bronchodilatador FEV1/FEV6 from microspirometry to detect airflow obstruction in primary care: a randomised cross-sectional study. Prim Care Respirat Med 2014;24, 14033.
- V. Wada H. Detection and prevalence of chronic obstructive pulmonary disease in a cardiovascular clinic: evaluation using a hand held FEV1/FEV6 meter and questionnaire. Respirology; 15(8): 1252-8.
- W. Muller M, Kogler H, Glaab T. COPD-screening in der hausärztlichen Praxis mit einem lungenfunktions-Schnellmessgerät. Pneumologie 2012; 66: 645-49

ANEXO 4. Estudios excluidos de nuestro trabajo, motivos de la exclusión de la revisión sistemática y citas bibliográficas.

- X. Schermer TR, Vatsolaki M, Behr R. Point of care microspirometry to facilitate the COPD diagnostic process in primary care: a clustered randomised trial. *Prim Care Respirat Med* 2018; 28:17
- Y. Sui ChF, Ming LCh, Neoh ChF. VitalQPlus: a potential screening tool for early diagnosis of COPD. *International J of COPD* 2015; 10: 1613- 22
- Z. Yawn BP, Duvalí K. the impact of screening tools on diagnosis of chronic chronic pulmonary disease in primary care. *Am J Prev Med* 2014; 47 (5): 563 – 75.
- AA. Pérez-Padilla R. Wehrmeister FC, Celli BR. Use of FEV6 and FEV1/FEV6 as alternative indicators in the diagnosis of bronchial obstruction in primary care. *Eur Resp Soc Congress* 2013
- AB. Kozaki M, Shimauchi M, Yatera K. Correlation of FEV1, FEV1/FEV6 and FEV1% between portable (Hi Checker) and conventional spirometer. *Chest* 2011; 140: 576A.
- AC. Moranta F, Gorreto L. Detección precoz de EPOC en las farmacias comunitarias de Baleares (FARBALEPOC). *Farmacéuticos Comunitarios* 2015; 7(3): 7-13
- AD. Banka R, Mangharam A, Pinto L. the use of mini Wright peak flow meter device as a point-of-care screening tool for obstructive airway disease in resource-limited settings. *Eur Resp J* 2017 50: PA1176
- AE. Dickens A, Adab P, Fitzmaurice D. Evaluating a simple lung monitor as a screening test for COPD in primary care. *Eur Resp J* 2017; 50: PA921.
- AF. Kjeldgaard P, Lykkegaard J, Spillemose H. Multicenter study of the COPD-6 screening device: feasible for early detection of chronic obstructive pulmonary disease in primary care? *International Journal of COPD* 2017; 12: 2323- 31.
- AG. Banka R, Mangharam A, Pinto L. the use of mini Wright peak flow meter device as a point-of-care screening tool for obstructive airway disease in resourcelimited settings. *Eur Resp J* 2017 50: PA1176
- AH. Antón-García F, Pruteanu DF, Correcher-Salvador E. Uso de Vitalograph COPD-6 en atención primaria como herramienta para la deshabituación tabáquica, *Semergen* 2016; 42 (2): 75-80.